ScholarIQanswers from OpenAlex

Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2

PaperCitations, authors & open-access status

Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2 is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2 have?

ScholarIQcitation count

Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2 has 652 citations in the OpenAlex counts ScholarIQ stores.

When was Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2 published?

ScholarIQyear

Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2 has 2002 year in the ScholarIQ index.

What is the open-access status of Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2?

ScholarIQoa status

Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2 has closed oa status in the ScholarIQ index.

What is the DOI of Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2?

ScholarIQdoi

The DOI for Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2 is on the source record.

What is the PMID of Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2?

ScholarIQpmid

The PMID for Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2 is on the source record.

What is the OpenAlex record for Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2?

ScholarIQopenalex

The OpenAlex for Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2 is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial